poisar

Stock

Neurogene Inc. NGNE

$36.14+1.43%

Overview

NGNE market data

Price History

NGNE price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$4.24
Diluted earnings per share over the trailing twelve months.
Beta
1.68
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-8,123.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$15.93 – $43.66
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $721.7M · P/B 1.20.

Company News

9 captured
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166Benzinga · Aug 12, 2026, 3:53 PM
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81Benzinga · Aug 12, 2026, 12:31 PM
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65Benzinga · Aug 12, 2026, 11:40 AM
Neurogene Q2 EPS $(1.53) Misses $(1.39) EstimateBenzinga · Aug 11, 2026, 11:45 AM
8-K filing — Neurogene Inc. (NGNE)SEC EDGAR · Aug 11, 2026, 11:32 AM
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded WarrantsBenzinga · Jul 1, 2026, 11:10 AM
Neurogene Reveals Proposed Public Offering; No Size DisclosedBenzinga · Jun 30, 2026, 8:05 PM
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett SyndromeBenzinga · Jun 29, 2026, 11:25 AM
Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett SyndromeBenzinga · Jun 8, 2026, 11:40 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock